ATLANTA, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the quarter ended June 30, 2016.
Second Quarter Highlights
* Second quarter 2016 global revenue increased 66% compared to the second quarter of 2015
Second Quarter Highlights
* Second quarter 2016 global revenue increased 66% compared to the second quarter of 2015
